Skip to main content
Top
Published in: BMC Gastroenterology 1/2019

Open Access 01-12-2019 | Hepatitis B | Research article

Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study

Authors: Hailemichael Desalegn, Hanna Aberra, Nega Berhe, Girmay Medhin, Bitsatab Mekasha, Svein Gunnar Gundersen, Asgeir Johannessen

Published in: BMC Gastroenterology | Issue 1/2019

Login to get access

Abstract

Background

Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients. In this study we aimed to assess predictors of mortality in one of the largest CHB cohorts in sub-Saharan Africa.

Methods

Two-hundred-and-seventy-six CHB patients who started treatment with tenofovir disoproxil fumarate at a public hospital in Ethiopia between March 18, 2015, and August 1, 2017, were included in this analysis. Patients were followed up until October 1, 2017, and deaths were ascertained through hospital records and telephone interview with relatives. Decompensated cirrhosis was defined as current or past evidence of ascites, either by clinical examination or by ultrasonography. Cox proportional hazard models were used to identify independent predictors of mortality.

Results

Thirty-five patients (12.7%) died during follow-up, 33 of whom had decompensated cirrhosis at recruitment. The median duration from start of treatment to death was 110 days (interquartile range 26–276). The estimated survival was 90.3, 88.2 and 86.3% at 6, 12 and 24 months of follow-up, respectively. Independent predictors of mortality were decompensated cirrhosis (adjusted hazard ratio [AHR] 23.68; 95% CI 3.23–173.48; p = 0.002), body mass index < 18.5 kg/m2 (AHR 3.65; 95% CI 1.73–7.72; p = 0.001) and older age (per 1-year increment; AHR 1.06; 95% CI 1.02–1.10; p = 0.007).

Conclusions

Decompensated cirrhosis, low body mass index and older age were independent predictors of mortality. Improved access to antiviral treatment and earlier initiation of therapy could improve the survival of African CHB patients.

Trial registration

NCT02344498 (ClinicalTrials.​gov identifier). Registered 16 January 2015.
Literature
2.
go back to reference World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva: WHO; 2016. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva: WHO; 2016.
3.
go back to reference World Health Organization (WHO). Global hepatitis report, 2017. Geneva: WHO; 2017. World Health Organization (WHO). Global hepatitis report, 2017. Geneva: WHO; 2017.
4.
go back to reference Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75.CrossRef Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75.CrossRef
5.
go back to reference Kim WR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121:3631–8.CrossRef Kim WR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121:3631–8.CrossRef
6.
go back to reference Beguelin C, Fall F, Seydi M, Wandeler G. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. Expert Rev Gastroenterol Hepatol. 2018;12:537–46. Beguelin C, Fall F, Seydi M, Wandeler G. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. Expert Rev Gastroenterol Hepatol. 2018;12:537–46.
7.
go back to reference Chen CF, Lee WC, Yang HI, et al. Risk evaluation of viral load elevation and associated liver disease/cancer in HBV (REVEAL-HBV) study group changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141:1240–8.CrossRef Chen CF, Lee WC, Yang HI, et al. Risk evaluation of viral load elevation and associated liver disease/cancer in HBV (REVEAL-HBV) study group changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141:1240–8.CrossRef
8.
go back to reference Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86.CrossRef Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86.CrossRef
9.
go back to reference Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610–4.CrossRef Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610–4.CrossRef
10.
go back to reference Park JG, Lee YR, Park SY, et al. Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B. Dig Liver Dis. 2018;50:163–7.CrossRef Park JG, Lee YR, Park SY, et al. Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B. Dig Liver Dis. 2018;50:163–7.CrossRef
12.
go back to reference Belyhun Y, Maier M, Mulu A, et al. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:761.CrossRef Belyhun Y, Maier M, Mulu A, et al. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:761.CrossRef
13.
go back to reference Aberra H, Desalegn H, Berhe N, et al. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis. 2017;17:438.CrossRef Aberra H, Desalegn H, Berhe N, et al. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis. 2017;17:438.CrossRef
14.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRef
15.
go back to reference Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016;65:1369–76.CrossRef Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016;65:1369–76.CrossRef
16.
go back to reference Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 2012;7:e44930.CrossRef Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 2012;7:e44930.CrossRef
18.
go back to reference von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.
19.
go back to reference Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52.CrossRef Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52.CrossRef
20.
go back to reference Srivastava M, Rungta S, Dixit VK, et al. Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective. Antivir Res. 2013;100:300–5.CrossRef Srivastava M, Rungta S, Dixit VK, et al. Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective. Antivir Res. 2013;100:300–5.CrossRef
21.
go back to reference Roongpisuthipong C, Sobhonslidsuk A, Nantiruj K, Songchitsomboon S. Nutritional assessment in various stages of liver cirrhosis. Nutrition. 2001;17:761–5.CrossRef Roongpisuthipong C, Sobhonslidsuk A, Nantiruj K, Songchitsomboon S. Nutritional assessment in various stages of liver cirrhosis. Nutrition. 2001;17:761–5.CrossRef
22.
go back to reference Nunes G, Santos CA, Barosa R, Fonseca C, Barata AT, Fonseca J. Outcome and nutritional assessment of chronic liver disease patients using anthropometry and subjective global assessment. Arq Gastroenterol. 2017;54:225–31.CrossRef Nunes G, Santos CA, Barosa R, Fonseca C, Barata AT, Fonseca J. Outcome and nutritional assessment of chronic liver disease patients using anthropometry and subjective global assessment. Arq Gastroenterol. 2017;54:225–31.CrossRef
23.
go back to reference Gunsar F, Raimondo ML, Jones S, et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther. 2006;24:563–72.CrossRef Gunsar F, Raimondo ML, Jones S, et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther. 2006;24:563–72.CrossRef
24.
go back to reference Lautz HU, Selberg O, Korber J, Burger M, Muller MJ. Protein calorie malnutrition in liver cirrhosis. Clin Investig. 1992;70:478–86.CrossRef Lautz HU, Selberg O, Korber J, Burger M, Muller MJ. Protein calorie malnutrition in liver cirrhosis. Clin Investig. 1992;70:478–86.CrossRef
25.
go back to reference Johnson TM, Overgard EB, Cohen AE, DiBaise JK. Nutrition assessment and management in advanced liver disease. Nutr Clin Pract. 2013;28:15–29.CrossRef Johnson TM, Overgard EB, Cohen AE, DiBaise JK. Nutrition assessment and management in advanced liver disease. Nutr Clin Pract. 2013;28:15–29.CrossRef
26.
go back to reference Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, CA: Lifetime Learning Publications; 1982. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, CA: Lifetime Learning Publications; 1982.
Metadata
Title
Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study
Authors
Hailemichael Desalegn
Hanna Aberra
Nega Berhe
Girmay Medhin
Bitsatab Mekasha
Svein Gunnar Gundersen
Asgeir Johannessen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2019
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-019-0993-1

Other articles of this Issue 1/2019

BMC Gastroenterology 1/2019 Go to the issue